How to Switch from Compounded to Brand-Name GLP-1 Without Losing Progress

The transition from compounded to brand-name GLP-1 doesn't have to mean starting over. Here's how to switch smoothly while maintaining your weight loss momentum.

Why the Switch Is Coming

Whether the FDA's 503B exclusion takes effect in Q3 2026 or later, the direction is clear: large-scale compounding of GLP-1 medications is ending. For millions of patients on compounded semaglutide or tirzepatide, a transition to brand-name medication is increasingly likely.

The good news: the active ingredient is the same. Compounded semaglutide and brand-name Wegovy/Ozempic contain the same molecule. The transition is about logistics, not pharmacology.

Step 1: Dosing Equivalency

This is where patients make the most common mistake. Compounded semaglutide is typically dosed in milligrams (e.g., 0.5 mg, 1.0 mg, 2.0 mg, 2.5 mg weekly). Brand-name Wegovy uses the same milligram dosing. The conversion is 1:1 for semaglutide.

For tirzepatide (Zepbound/Mounjaro), the standard doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly. If your compounded dose matches a standard tier, the switch is straightforward. If you're on a non-standard dose (e.g., 3.75 mg), your prescriber may need to round to the nearest standard dose and monitor closely.

Critical: do not switch doses simultaneously with switching formats. Stay on your current dose when you switch to brand-name, even if you've been considering a dose change. Stabilize on the new format first, then adjust dosing if needed.

Step 2: Access Brand-Name Savings

NovoCare (Wegovy/Ozempic)

Novo Nordisk's savings program reduces the out-of-pocket cost for eligible patients. The specifics depend on your insurance status: commercially insured patients with coverage may pay as little as $0–25/month. Cash-pay patients without insurance typically pay $500–600/month through the program. Oral Wegovy starts at $149/month through manufacturer savings for the introductory 1.5 mg dose.

LillyDirect (Zepbound/Mounjaro)

Eli Lilly's direct-to-patient platform offers Zepbound starting at $399/month for lower doses for self-pay patients. Some telehealth providers can route prescriptions through LillyDirect for automated savings application.

Step 3: Insurance Authorization

If you have health insurance, brand-name GLP-1 coverage varies dramatically by plan. Many commercial plans now cover Wegovy or Zepbound with prior authorization. The prior auth process typically requires documented BMI ≥30 (or ≥27 with comorbidities), a physician's statement of medical necessity, and sometimes evidence of a previous weight loss attempt.

Your prescriber handles the prior auth, but you can speed the process by providing them with current lab work (A1C, lipid panel), documented weight history, and any prior authorization documentation from your compounding provider.

Step 4: Manage the Transition

The physical switch is simple: your last compounded injection is one week, your first brand-name injection is the next. No washout period is needed. Some patients report slightly different side effect profiles between compounded and brand-name versions — this is likely due to differences in excipients (inactive ingredients) rather than the active medication.

If you experience new or different side effects after switching, they typically resolve within 2–4 weeks as your body adjusts to the new formulation. Contact your provider if anything seems concerning.